135 related articles for article (PubMed ID: 33370338)
1. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
[TBL] [Abstract][Full Text] [Related]
2. Resensitizing Paclitaxel-Resistant Ovarian Cancer via Targeting Lipid Metabolism Key Enzymes CPT1A, SCD and FASN.
Ma Q; Liu Z; Wang T; Zhao P; Liu M; Wang Y; Zhao W; Yuan Y; Li S
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003694
[TBL] [Abstract][Full Text] [Related]
3. Mutation characteristics and molecular evolution of ovarian metastasis from gastric cancer and potential biomarkers for paclitaxel treatment.
Yu P; Hu C; Ding G; Shi X; Xu J; Cao Y; Chen X; Wu W; Xu Q; Fang J; Huang X; Yuan S; Chen H; Wang Z; Huang L; Pang F; Du Y; Cheng X
Nat Commun; 2024 May; 15(1):3771. PubMed ID: 38704377
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
[TBL] [Abstract][Full Text] [Related]
5. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy.
Cole AJ; Panesso-Gómez S; Shah JS; Ebai T; Jiang Q; Gumusoglu-Acar E; Bello MG; Vlad A; Modugno F; Edwards RP; Buckanovich RJ
Clin Cancer Res; 2023 May; 29(10):1969-1983. PubMed ID: 36795892
[TBL] [Abstract][Full Text] [Related]
6. Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases.
Erol A; Niemira M; Krętowski AJ
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31146417
[TBL] [Abstract][Full Text] [Related]
7. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract][Full Text] [Related]
8. MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.
Xu K; Zheng X; Shi H; Ou J; Ding H
Sci Rep; 2024 Jan; 14(1):130. PubMed ID: 38167649
[TBL] [Abstract][Full Text] [Related]
9. Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations.
Lee AH; Mejia Peña C; Dawson MR
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326569
[TBL] [Abstract][Full Text] [Related]
10. RSK4 confers paclitaxel resistance to ovarian cancer cells, which is resensitized by its inhibitor BI-D1870.
Nagumo Y; Villareal MO; Isoda H; Usui T
Biochem Biophys Res Commun; 2023 Oct; 679():23-30. PubMed ID: 37660640
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
[TBL] [Abstract][Full Text] [Related]
12. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract][Full Text] [Related]
13. GADD45B Facilitates Metastasis of Ovarian Cancer Through Epithelial-Mesenchymal Transition.
Gong L; Cai L; Li G; Cai J; Yi X
Onco Targets Ther; 2021; 14():255-269. PubMed ID: 33469306
[TBL] [Abstract][Full Text] [Related]
14. Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma.
Perrone G; Rigacci L; Urru S; Kovalchuk S; Brugia M; Fabbri A; Iovino L; Puccini B; Cencini E; Orciuolo E; Birtolo S; Melosi A; Santini S; Landini I; Roviello G; Santi R; Macciotta A; Ricceri F; Bosi A; Bocchia M; Petrini M; Mini E; Nobili S
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345090
[TBL] [Abstract][Full Text] [Related]
15. Receptors that bind to PEDF and their therapeutic roles in retinal diseases.
Xu M; Chen X; Yu Z; Li X
Front Endocrinol (Lausanne); 2023; 14():1116136. PubMed ID: 37139333
[TBL] [Abstract][Full Text] [Related]
16. The chemistry and efficacy benefits of polysaccharides from
Liu C; Wang S; Xiang Z; Xu T; He M; Xue Q; Song H; Gao P; Cong Z
Front Pharmacol; 2022; 13():952061. PubMed ID: 36091757
[No Abstract] [Full Text] [Related]
17. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
18. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
19. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells.
Wang AC; Su QB; Wu FX; Zhang XL; Liu PS
Eur J Clin Invest; 2009 Feb; 39(2):157-64. PubMed ID: 19200169
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
